{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:15Z","timestamp":1789749495085,"version":"4.0.1"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Extraintestinal manifestations (EIMs) pose a significant threat in inflammatory bowel disease (IBD) patients. Vedolizumab (VDZ) primarily affects the gastrointestinal tract. However, its impact on EIMs remains uncertain. Therefore, we conducted this meta\u2010analysis to examine the effects of VDZ on EIMs during treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant studies were identified by conducting thorough searches across electronic databases, including PubMed, Ovid Embase, Medline, and Cochrane CENTRAL. Primary outcomes focused on the proportion of patients with resolution for pre\u2010existing EIMs in IBD patients receiving VDZ. Secondary outcomes included the proportion of patients with EIM exacerbations and new onset EIMs during VDZ treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our meta\u2010analysis encompassed 21 studies. The proportion of patients with resolution of pre\u2010existing EIMs in VDZ\u2010treated IBD patients was 39% (150\/386; 95% confidence interval [CI] 0.31\u20130.48). The proportion of patients with EIM exacerbations occurred at a rate of 28% (113\/376; 95% CI 0.05\u20130.50), while new onset EIMs had a rate of 15% (397\/2541; 95% CI 0.10\u20130.20). Subgroup analysis revealed a 40% (136\/337) proportion of patients with resolution for articular\u2010related EIMs and a 50% (9\/18) rate for erythema nodosum. Exacerbation rates for arthritis\/arthralgia, erythema nodosum\/pyoderma gangrenosum, and aphthous stomatitis during VDZ use were 28% (102\/328), 18% (7\/38), and 11% (3\/28), respectively. The incidence rate of newly developed EIMs during treatment was 11% (564\/4839) for articular\u2010related EIMs, with other EIMs below 2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>VDZ demonstrates efficacy in skin\u2010related EIMs like erythema nodosum and joint\u2010related EIMs including arthritis, arthralgia, spondyloarthritis, and peripheral joint diseases. Some joint and skin\u2010related EIMs may experience exacerbation during VDZ therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jgh.16612","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:44:33Z","timestamp":1715651073000},"page":"1745-1759","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"39","author":[{"given":"Dian\u2010yu","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Gastroenterology First Hospital of China Medical University  Shenyang City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010nuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Hospital of China Medical University  Shenyang City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Hong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Hospital of China Medical University  Shenyang City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Hospital of China Medical University  Shenyang City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010nan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Hospital and College of Basic Medical Sciences China Medical University  Shenyang City China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-183X","authenticated-orcid":false,"given":"Cong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Hospital of China Medical University  Shenyang City China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac058"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000392"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy191"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1574569"},{"key":"e_1_2_6_6_1","first-page":"147","article-title":"Designing biologic selectivity for inflammatory bowel disease\u2014role of vedolizumab","volume":"9","author":"Krupka N","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.2.517"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.236"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy125"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620965106"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa078"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.09.009"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.02.013"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002527"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.06.038"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-211011"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14419"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad075"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa293"},{"key":"e_1_2_6_22_1","first-page":"75","article-title":"Vedolizumab\u2010induced de novo extraintestinal manifestations","volume":"16","author":"Diaz LI","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa107"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.933357"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy065"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13594"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz088"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14525"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14829"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.013"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv213"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.03.040"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322129"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206323"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx158"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210233"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz095"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.16612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:40:47Z","timestamp":1746063647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.16612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/jgh.16612"],"URL":"https:\/\/doi.org\/10.1111\/jgh.16612","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"2023-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}